Posts

Dr. Natalie Wisniewski, of Profusa, Inc., gave some insight about her company’s non-dilutive funding journey, starting with their initial grant from DARPA in 2011 through to today.


Dr. James B. Phillips of USAMRMC, Department of Defense, shared with the audience the mission of the US Army Medical Research and Material Command and the Medical Technology Enterprise Consortium, discussing opportunities available for partnering and engaging with Industry.

View Slide Deck

Ram May-Ron, Managing Partner of the FreeMind Group, opened the 13th Annual Non-Dilutive Funding Summit with a few comments on the value of non-dilutive funding to the life sciences industry.

Ram May-Ron of the FreeMind Group opens the 12th Annual Non-Dilutive Funding Summit with a few remarks on recent trends in life science R&D funding and the importance of federal grants as a strategic source of funds.

Dr. Ronald Hann of the Defense Threat Reduction Agency (DTRA) presents the keynote address on Preparing for the Unthinkable.

 

View Slide Deck

Tyler Merkeley of the Biomedical Advanced Research and Development Authority (BARDA) CARB-X program talks about the novel non-dilutive partnership created to promote innovation and foster a robust antimicrobials pipeline.

 

View Slide Deck

Paul McQuade of Greenberg Traurig, LLP shares some legal aspects of federal technology investment and their potential impact on intended markets.

 

View Slide Deck

Dr. Todd Haim of the National Cancer Institute SBIR Development Center describes the NCI’s SBIR and STTR programs, their structure, the Institute’s funding interests, and FAQs.

 

View Slide Deck

Dr. Meg Mooney of the National Cancer Institute discusses new initiatives to accelerate development of cancer therapies in the era of precision medicine.

 

View Slide Deck

Mr. Henry Ahn of the National Science Foundation speaks on the NSF’s SBIR and STTR programs.

 

View Slide Deck